Navin Fluorine International Limited (NFIL) has reported a robust performance for the second quarter, with significant growth in revenue and profitability. The company's consolidated net profit more than doubled, showcasing strong operational efficiency and market demand for its products.

Financial Highlights

NFIL's Q2 results demonstrate substantial year-over-year improvements:

The company's performance shows a significant leap in profitability, with net profit rising by 152% compared to the same quarter last year. Revenue growth of 46% indicates strong market demand and possibly increased market share.

Operational Performance

NFIL's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a remarkable increase of 130%, reaching ₹246.00 crore. The EBITDA margin expanded substantially from 20.70% to 32.46%, reflecting improved operational efficiency and potentially better pricing power.

Dividend Declaration

The Board of Directors has declared an interim dividend of ₹6.50 per share (325%) on equity shares with a face value of ₹2 each for the financial year 2025-26. This declaration signals confidence in the company's financial health and commitment to shareholder returns.

Capital Expansion Plans

NFIL has announced significant capital expenditure plans:

1. An investment of ₹236.50 crore for expanding HFC (Hydrofluorocarbon) capacity by up to 15,000 MTPA R32 equivalent quantity at its Surat unit. This expansion aims to cater to growing demand in both domestic and export markets.

2. A ₹75.00 crore investment for debottlenecking the Multi Purpose Plant facility at Dahej through its wholly-owned subsidiary, Navin Fluorine Advanced Sciences Limited. This initiative is expected to accommodate additional product manufacturing and expand the company's product portfolio.

Equity Allotment

On October 29, 2025, NFIL allotted 8,500 equity shares under its Employees' Stock Option Scheme 2017, increasing its paid-up share capital to ₹10,24,70,188.

Future Outlook

With these strategic investments and strong financial performance, Navin Fluorine International appears well-positioned for continued growth. The expansion in HFC capacity and the debottlenecking of the Multi Purpose Plant are expected to strengthen the company's market position and potentially lead to increased revenues in the coming quarters.

The company's focus on expanding its product range, particularly in fluoro intermediates for novel agrochemical products, indicates a strategy to deepen relationships with global innovators and diversify its revenue streams.

Navin Fluorine International Limited (NFIL) has commenced commercial production at Phase 1 of its new cGMP-4 facility in Dewas, marking the full operationalization of its ₹160 crore investment. The company announced on December 31, 2025, that commercial production began following successful validation of batches by its European partner.

Facility Investment and Specifications

The cGMP-4 facility represents a significant milestone in the company's expansion strategy. The completed Phase 1 facility details are outlined below:

Validation and Production Timeline

The facility has successfully completed its validation phase with a European partner, a critical step that preceded the commencement of commercial operations. This validation process ensures that the facility meets international quality standards and regulatory requirements essential for serving global pharmaceutical markets.

Strategic Development Phases

Navin Fluorine International has adopted a phased approach for the cGMP-4 facility development:

Regulatory Compliance and Market Position

The cGMP-4 designation indicates adherence to strict regulatory requirements, positioning the facility to serve global pharmaceutical markets effectively. The successful validation by a European partner demonstrates the facility's capability to meet international quality standards from the outset of operations.

Company Communication

In its regulatory filing to BSE and NSE, Navin Fluorine International stated that commercial production commenced following "successful validation of batches by our European partner." This development represents the culmination of the company's earlier announcements regarding the facility's construction completion and commissioning readiness.

The commencement of commercial production at the Dewas facility strengthens Navin Fluorine's manufacturing capabilities and enhances its position in the specialty chemicals and pharmaceutical intermediates sectors.